Mantle cell lymphoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Mantle cell lymphoma accounts for 4–8% of all adult non-Hodgkin’s lymphomas (NHL). It has an incidence of approximately 1-2/100000 and tends to occur more in males, Caucasian race, with a median age of about 60 years. | [[Mantle cell lymphoma]] accounts for 4–8% of all adult [[Non-Hodgkin lymphoma|non-Hodgkin’s lymphomas]] (NHL). It has an [[incidence]] of approximately 1-2/100000 and tends to occur more in [[males]], Caucasian race, with a median [[age]] of about 60 years. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
* The annual incidence of mantle cell lymphoma has increased during recent decades to 1–2/100 000 recently.<ref>{{Cite journal | * The annual [[incidence]] of [[mantle cell lymphoma]] has increased during recent decades to 1–2/100 000 recently.<ref>{{Cite journal | ||
| author = [[M. Dreyling]], [[C. Geisler]], [[O. Hermine]], [[H. C. Kluin-Nelemans]], [[S. Le Gouill]], [[S. Rule]], [[O. Shpilberg]], [[J. Walewski]] & [[M. Ladetto]] | | author = [[M. Dreyling]], [[C. Geisler]], [[O. Hermine]], [[H. C. Kluin-Nelemans]], [[S. Le Gouill]], [[S. Rule]], [[O. Shpilberg]], [[J. Walewski]] & [[M. Ladetto]] | ||
| title = Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | | title = Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | ||
| Line 22: | Line 22: | ||
===Age=== | ===Age=== | ||
*The median age at diagnosis for mantle cell lymphoma is about 60 years.<ref>{{Cite journal | *The median [[age]] at [[diagnosis]] for [[mantle cell lymphoma]] is about 60 years.<ref>{{Cite journal | ||
| author = [[Arati A. Inamdar]], [[Andre Goy]], [[Nehad M. Ayoub]], [[Christen Attia]], [[Lucia Oton]], [[Varun Taruvai]], [[Mark Costales]], [[Yu-Ting Lin]], [[Andrew Pecora]] & [[K. Stephen Suh]] | | author = [[Arati A. Inamdar]], [[Andre Goy]], [[Nehad M. Ayoub]], [[Christen Attia]], [[Lucia Oton]], [[Varun Taruvai]], [[Mark Costales]], [[Yu-Ting Lin]], [[Andrew Pecora]] & [[K. Stephen Suh]] | ||
| title = Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents | | title = Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents | ||
| Line 36: | Line 36: | ||
===Race=== | ===Race=== | ||
*Mantle cell lymphoma tends to affect Caucasians more than African-Americans.<ref>{{Cite journal | *[[Mantle cell lymphoma]] tends to affect Caucasians more than African-Americans.<ref>{{Cite journal | ||
| author = [[Yuhong Zhou]], [[Haijun Wang]], [[Wenjing Fang]], [[Jorge E. Romaguer]], [[Yanxia Zhang]], [[Kay B. Delasalle]], [[Larry Kwak]], [[Qing Yi]], [[Xianglin L. Du]] & [[Michael Wang]] | | author = [[Yuhong Zhou]], [[Haijun Wang]], [[Wenjing Fang]], [[Jorge E. Romaguer]], [[Yanxia Zhang]], [[Kay B. Delasalle]], [[Larry Kwak]], [[Qing Yi]], [[Xianglin L. Du]] & [[Michael Wang]] | ||
| title = Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004 | | title = Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004 | ||
| Line 49: | Line 49: | ||
}}</ref> | }}</ref> | ||
===Gender=== | ===Gender=== | ||
*Males are more commonly affected by mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.<ref>{{Cite journal | *[[Males]] are more commonly affected by [[mantle cell lymphoma]] than [[females]]. The male to female ratio is approximately 4 to 1.<ref>{{Cite journal | ||
| author = [[Arati A. Inamdar]], [[Andre Goy]], [[Nehad M. Ayoub]], [[Christen Attia]], [[Lucia Oton]], [[Varun Taruvai]], [[Mark Costales]], [[Yu-Ting Lin]], [[Andrew Pecora]] & [[K. Stephen Suh]] | | author = [[Arati A. Inamdar]], [[Andre Goy]], [[Nehad M. Ayoub]], [[Christen Attia]], [[Lucia Oton]], [[Varun Taruvai]], [[Mark Costales]], [[Yu-Ting Lin]], [[Andrew Pecora]] & [[K. Stephen Suh]] | ||
| title = Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents | | title = Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents | ||
Revision as of 19:31, 18 December 2018
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma epidemiology and demographics |
|
Mantle cell lymphoma epidemiology and demographics in the news |
|
Risk calculators and risk factors for Mantle cell lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
Mantle cell lymphoma accounts for 4–8% of all adult non-Hodgkin’s lymphomas (NHL). It has an incidence of approximately 1-2/100000 and tends to occur more in males, Caucasian race, with a median age of about 60 years.
Epidemiology and Demographics
Incidence
- The annual incidence of mantle cell lymphoma has increased during recent decades to 1–2/100 000 recently.[1]
Age
- The median age at diagnosis for mantle cell lymphoma is about 60 years.[2]
Race
- Mantle cell lymphoma tends to affect Caucasians more than African-Americans.[3]
Gender
- Males are more commonly affected by mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.[4]
References
- ↑ M. Dreyling, C. Geisler, O. Hermine, H. C. Kluin-Nelemans, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski & M. Ladetto (2014). "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of oncology : official journal of the European Society for Medical Oncology. 25 Suppl 3: iii83–iii92. doi:10.1093/annonc/mdu264. PMID 25210087. Unknown parameter
|month=ignored (help) - ↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter
|month=ignored (help) - ↑ Yuhong Zhou, Haijun Wang, Wenjing Fang, Jorge E. Romaguer, Yanxia Zhang, Kay B. Delasalle, Larry Kwak, Qing Yi, Xianglin L. Du & Michael Wang (2008). "Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004". Cancer. 113 (4): 791–798. doi:10.1002/cncr.23608. PMID 18615506. Unknown parameter
|month=ignored (help) - ↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter
|month=ignored (help)